Parabilis Medicines annual ebitda
2024
2025
Parabilis Medicines EBITDA Growth & History (PBLS)
Parabilis Medicines's calculated EBITDA was −$149.6M for fiscal 2025.
View full Parabilis Medicines company overviewParabilis Medicines annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$149.6M | −$25.6M | — |
| 2024 | 2024-12-31 | −$124.0M | — | — |
Parabilis Medicines quarterly ebitda
Q1.25
Q2.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$50.3M | −$14.0M | — |
| Q1 2026 | 2026-03-31 | −$44.4M | −$7.1M | — |
| Q2 2025 | 2025-06-30 | −$36.3M | — | — |
| Q1 2025 | 2025-03-31 | −$37.3M | — | — |
Parabilis Medicines ebitda trends
Between the periods ended 2024-12-31 and 2025-12-31, Parabilis Medicines's ebitda decreased from −$124.0M to −$149.6M, a change of −$25.6M. The latest reported quarter, Q2 2026, shows −$50.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Parabilis Medicines source filings ↗Community posts
Parabilis advances desmoid-tumor program after updated response data
Parabilis Medicines ($PBLS) reported a 72.2% response rate for investigational zolucatetide in a 32-week analysis of desmoid-tumor patients who started at doses of at least 450 milligrams. That figure represents 13 responses among 18 evalua ...
